# Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

> **NCT00421187** · PHASE4 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 20 (actual)

## Conditions studied

- Febrile Neutropenia

## Interventions

- **DRUG:** Liposomal amphotericin B (AmBisome®)
- **DRUG:** Liposomal amphotericin B (AmBisome®)

## Key facts

- **NCT ID:** NCT00421187
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2008-04
- **Final completion:** 2008-05
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Unable to recruit subjects in the Turkey site.
- **Last updated:** 2011-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421187, "Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00421187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*